# Clinical Trial Protocol
# Iranian Registry of Clinical Trials

23 Feb 2026

## Investigation of the effect of artemisinin Capsules and Dermaneh (Artemisia persica)and Afsantin)Artemisia absinthium( Capsules in the treatment of coronavirus COVID-19 virus in Afzalipour hospital,kerman, 2020

### Protocol summary

**Study aim**
Investigation of the effect of artemisinin Capsules, Dermaneh (Artemisia persica) Capsules and Afsantin (Artemisia absinthium) Capsules on the treatment of patients with corona (COVID-19)

**Design**
A randomized, controlled, three-blind, placebo-controlled clinical trial, triple-blind, randomized, phase 2 on 30 patients. The table of random numbers is used for randomization.

**Settings and conduct**
Afzalipour hospital, Kerman, 2020, Care provider, Investigator, outcome assessor and data analyzer are blind. The drugs were the same in color and same shape. Care provider, Investigator, outcome assessor and data analyzer are blind did not know anything about the drug.

**Participants/Inclusion and exclusion criteria**
Inclusion criteria: Signing consent form; Age 18-65 years old; PCR positive test or characteristic signs on a CT scan of the chest with mild to moderate clinical manifestations according to the National Early Warning Score (NEWS) Exclusion criteria: Severe liver disease; Severe renal disease; allergic reaction to used drugs in study; Pregnant or breastfeeding women; transfer to the intensive care unit.

**Intervention groups**
The intervention group will receive 100 mg artemisinin, two Dermaneh capsules and two Afsantin capsules the control group will receive placebo capsules daily. Patients will be given daily capsules in packs containing 70capsules and we ask patients to take five capsules daily for 14 days.

**Main outcome variables**
Lymphocytes,C-reactive protein, Respiratory Rate, Oxygen saturation, Headache, Muscle pain, Sore throat, Anorexia, Fatigue and Cough

### General information

**Reason for update**

**Acronym**

**IRCT registration information**
IRCT registration number: **IRCT20201027049164N6**
Registration date: **2022-03-29, 1401/01/09**
Registration timing: **retrospective**

Last update: **2022-03-29, 1401/01/09**
Update count: **0**

**Registration date**
2022-03-29, 1401/01/09

**Registrant information**

**Name**
Masumeh Ghazanfarpour

**Name of organization / entity**

**Country**
Iran (Islamic Republic of)

**Phone**
+98 34 3132 5856

**Email address**
m.ghazanfarpour@kmu.ac.ir

**Recruitment status**
**Recruitment complete**

**Funding source**

**Expected recruitment start date**
2020-11-10, 1399/08/20

**Expected recruitment end date**
2021-02-18, 1399/11/30

**Actual recruitment start date**
empty

**Actual recruitment end date**
empty

**Trial completion date**

empty

**Scientific title**
Investigation of the effect of artemisinin Capsules and Dermaneh (Artemisia persica)and Afsantin)Artemisia absinthium( Capsules in the treatment of coronavirus COVID-19 virus in Afzalipour hospital,kerman, 2020

**Public title**
Investigation of the effect of artemisinin and Dermaneh and Afsantinin the treatment of coronavirus COVID-19 virus

**Purpose**
Treatment

**Inclusion/Exclusion criteria**

**Inclusion criteria:**
Patients with signing Informed Consent Age 18-65 years old Positive CRP test for SARS-CoV-2 virus or characteristic signs on a CT scan of the chest with mild to moderate clinical manifestations according to the National Early Warning Score (NEWS) (mild: 1-4 / moderate: 5-6)

**Exclusion criteria:**
Receipt of any another experimental treatment Severe liver disease Known allergic reaction to drugs Severe renal disease Pregnant or breastfeeding women transfer to the intensive care unit

**Age**
From **18 years** old to **65 years** old

**Gender**
Both

**Phase**
3

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

**Sample size**
Target sample size: **30**

**Randomization (investigator's opinion)**
Randomized

**Randomization description**
For randomization, the table of random numbers will be used. First, a code from 01 to 30, was given to patient. The first 15 was used for intervention group whereas the other15 for the control. We placed a finger on the columns of the random numbers table to determine start point, and the last two digits of each column were considered. It was ignored if numbers were higher For example, 23 code received placebo.

**Blinding (investigator's opinion)**
Double blinded

**Blinding description**
Researchers, nurses, and patients will be not aware of medication or placebo because they will be similar in appearance

**Placebo**
Used

**Assignment**
Parallel

**Other design features**

## Secondary Ids

empty

## Ethics committees

### 1

**Ethics committee**

**Name of ethics committee**
Ethics committee of Kerman University of Medical Sciences

**Street address**
Deputy of Research and Technology;ebne-e-Sina St.,Jahad Blvd., Kerman,Iran

**City**
Kerman

**Province**
Kerman

**Postal code**
7619813159

**Approval date**
2020-10-24, 1399/08/03

**Ethics committee reference number**
IR.KMU.REC.1399.292

## Health conditions studied

### 1

**Description of health condition studied**
COVID-19

**ICD-10 code**
U07.1

**ICD-10 code description**
COVID-19, virus identified

## Primary outcomes

### 1

**Description**
Oxygen saturation

**Timepoint**
At the beginning (before the intervention) and 14 days after intervention

**Method of measurement**
Pulse Oximeter

### 2

**Description**
Respiratory Rate

**Timepoint**
At the beginning of the study (before the intervention) and14 days after intervention

**Method of measurement**
Respiratory Count

### 3

**Description**
C-reactive protein
**Timepoint**
At the beginning of the study (before the intervention) , 7 days after the intervention, 14 days after intervention
**Method of measurement**
Venous blood test

### 4

**Description**
Lymphocytes
**Timepoint**
At the beginning of the study (before the intervention) and 14 days after intervention
**Method of measurement**
Venous blood test

## Secondary outcomes

### 1

**Description**
Headache
**Timepoint**
At the beginning of the study (before the intervention) and 14 days after the intervention
**Method of measurement**
Questionnaire

### 2

**Description**
Muscle pain
**Timepoint**
At the beginning of the study (before the intervention) and 14 days after the intervention
**Method of measurement**
Questionnaire

### 3

**Description**
Sore throat
**Timepoint**
At the beginning of the study (before the intervention) and 14 days after the intervention
**Method of measurement**
Questionnaire

### 4

**Description**
Anorexia
**Timepoint**
At the beginning of the study (before the intervention) and 14 days after the intervention
**Method of measurement**
Questionnaire

### 5

**Description**
Fatigue
**Timepoint**
At the beginning of the study (before the intervention)and 14 days after the intervention
**Method of measurement**
Questionnaire

### 6

**Description**
Cough
**Timepoint**
At the beginning of the study (before the intervention) and 14 days after the intervention
**Method of measurement**
Questionnaire

## Intervention groups

### 1

**Description**
Intervention group: The intervention group will receive two Dermaneh capsules of artemisinin 100 mg, two capsules (each containing 5oo mg Dermaneh ) and two Dermaneh capsules (each containing 500 mg Afsantin) daily. Patients will be given daily capsules in packs containing 70capsules and we ask patients to take five capsules daily for 14 days.
**Category**
Treatment - Drugs

### 2

**Description**
Control group: The control group will receive placebo capsules daily. Patients will be given capsules in packs containing 84 capsules and we ask patients to take six capsules daily for 14 days.
**Category**
Treatment - Drugs

## Recruitment centers

### 1

**Recruitment center**
**Name of recruitment center**
Afzalipour hospital
**Full name of responsible person**
Masumeh Ghazanfarpour
**Street address**
Adjacent to Bahonar University, AfzaliPour Landscape, Imam highway, Kerman
**City**
Kerman
**Province**
Kerman
**Postal code**
۷۶۱۶۹۱۳۹۱۱

**Phone**
+98 34 3132 5700
**Email**
m.ghazanfarpour@kmu.ac.ir

## Sponsors / Funding sources

**1**

**Sponsor**
**Name of organization / entity**
Kerman University of Medical Sciences
**Full name of responsible person**
Dr. Abbas Pardakhti
**Street address**
Tahmasbabad cross road, Vice Chancellor for Research and Technology building
**City**
Kerman
**Province**
Kerman
**Postal code**
7616913555
**Phone**
+98 34 3132 5856
**Email**
m.ghazanfarpour@kmu.ac.ir
**Grant name**
**Grant code / Reference number**
**Is the source of funding the same sponsor organization/entity?**
No
**Title of funding source**
Vice Chancellor for Research and Technology of Kerman University of Medical Sciences
**Proportion provided by this source**
100
**Public or private sector**
Public
**Domestic or foreign origin**
Domestic
**Category of foreign source of funding**
*empty*
**Country of origin**
**Type of organization providing the funding**
Academic

## Person responsible for general inquiries

**Contact**
**Name of organization / entity**
Kerman University of Medical Sciences
**Full name of responsible person**
Masumeh Ghazanfarpour
**Position**
Assistant professor
**Latest degree**
Ph.D.
**Other areas of specialty/work**
Midwifery
**Street address**
Kerman University of Medical Sciences,Medical University Campus,Haft-Bagh Highway, Kerman, Ira
**City**
Kerman
**Province**
Kerman
**Postal code**
76169-13555
**Phone**
+98 34 3132 5700
**Email**
masumeh.ghazanfarpour@yahoo.com

## Person responsible for scientific inquiries

**Contact**
**Name of organization / entity**
Kerman University of Medical Sciences
**Full name of responsible person**
Masumeh Ghazanfarpour
**Position**
Assistant professor
**Latest degree**
Ph.D.
**Other areas of specialty/work**
Midwifery
**Street address**
Kerman University of Medical Sciences,Medical University Campus,Haft-Bagh Highway, Kerman, Iran
**City**
Kerman
**Province**
Kerman
**Postal code**
7616913555
**Phone**
+98 34 3132 5856
**Email**
Masumeh.ghazanfarpour@yahoo.com

## Person responsible for updating data

**Contact**
**Name of organization / entity**
Kerman University of Medical Sciences
**Full name of responsible person**
Masumeh Ghazanfarpour
**Position**
Assistant Professor
**Latest degree**
Ph.D.
**Other areas of specialty/work**
Midwifery
**Street address**
Beginning of the axis of seven Alavi Gardens, Campus of the University of Medical Sciences, Faculty of Nursing and Midwifery
**City**
Kerman
**Province**
Kerman
**Postal code**

7616913555

**Phone**

+98 34 3132 5700

**Email**

M.ghazanfarpour@kmu.ac.ir

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available